Skip to main content
Erschienen in: BMC Medical Imaging 1/2017

Open Access 01.12.2017 | Research article

The value of 99mTc-methylene diphosphonate single photon emission computed tomography/computed tomography in diagnosis of fibrous dysplasia

verfasst von: Linqi Zhang, Qiao He, Wei Li, Rusen Zhang

Erschienen in: BMC Medical Imaging | Ausgabe 1/2017

Abstract

Background

Fibrous dysplasia (FD) is a rare benign bone disorder in which the normal bone is replaced by immature fibro-osseous tissue. However, some case reports have reported that FD showed significantly increased 99mTc-methylene diphosphonate (99mTc-MDP) uptake on whole-body bone scintigraphy (WBS), which may mimic bone metastasis or skeletal involvement of the patients with known cancer. Thus, the purpose of present study is to observe the reliable characteristics and usefulness of single photon emission computed tomography/computed tomography (SPECT/CT) for the diagnosis of FD.

Methods

This was a retrospective review of 21 patients with FD (14 males and 7 females, mean age 51.2 ± 12.5 years) who were referred to have WBS to determine whether there was any osseous metastasis. WBS and SPECT/CT images were independently interpreted by two experienced nuclear medicine physician together with a diagnostic radiologist. In cases of discrepancy, consensus was obtained by a joint reading. The final diagnosis was based on biopsy proof and radiologic follow-up over at least 1 year.

Results

The lesions of FD were most frequently found in craniofacial region (15/21). Eighteen of the 21 (85.7%) cases showed moderate and high metabolism on WBS (compared to sternum). On CT imaging, GGO and expansion were the most common finding, were noted in 90.5% and 85.7% of the patients. Lytic lesions were present in 61.9% of the patients, and sclerosis was present in 38.1% of the patients. Cortical disruption was not seen in any patient.

Conclusions

FD has certain characteristic appearance on SPECT/CT. It should be enrolled in the differential diagnoses when lesions show elevated 99mTc-MDP uptake on WBS. For SPECT/CT, the CT features of GGO and expansion in the areas of abnormal radiotracer uptake are helpful for the diagnosis of FD.
Abkürzungen
99mTc-MDP
99mTc-methylene diphosphonate
FD
Fibrous dysplasia
SPECT/CT
Single photon emission computed tomography/computed tomography.
WBS
whole-body bone scintigraphy

Background

Fibrous dysplasia (FD) is a rare benign bone disorder in which the normal bone is replaced by immature fibro-osseous tissue. The actual prevalence of FD is difficult to estimate, but it may affect about 1/30,000 persons with a similar distribution around the world. The disease may involve single bone (monostotic FD, 70%) or multiple bones (polyostotic FD, 30%) with a predilection for the craniofacial bones and ribs. Patients are usually asymptomatic and detected incidentally on imaging studies that are performed for other purposes. In rare symptomatic cases, FD can present as bone pain, deformity, or pathologic fracture [1, 2]. 99mTc-MDP (99mTc-labeled methylene diphosphonate) whole-body bone scans (WBS) has been widely used for detection of metastasis for various malignant diseases. However, some case reports have reported that FD showed significantly increased 99mTc-MDP uptake, which may mimic bone metastasis or skeletal involvement of the patients with known cancer [35]. Therefore, active diagnosis and radiological familiarity of FD are thought to be essential for distinguishing bone metastasis and preventing unnecessary examinations or therapy. Single photon emission computed tomography/computed tomography (SPECT/CT) offers the opportunity to obtain diagnostic-quality CT and SPECT images, hence enabling more accurate localization and characterization of SPECT lesions using the CT component. However, the SPECT/CT features of FD have not been summarized. In present study, we wished to observe the reliable characteristics and usefulness of SPECT/CT in a larger cohort of patients with FD.

Methods

Patients

A total of 27,859 patients underwent 99mTc-MDP WBS from March 2009 to January 2017 at Department of Nuclear Medicine. Among which, there were 8517 patients had SPECT/CT for further evaluation. Of these patients, twenty one patients (fourteen males and seven females, mean age 51.2 ± 12.5 years, age range 23 ~ 70 years) found to have FD were recruited in the study. In 13 cases, the clinician performed biopsies to determine whether there was any osseous metastasis, because the anatomic site of the lesion was easily accessible. Pathologic analysis confirmed the diagnosis of FD. In 8 cases, the patients had been diagnosed based on radiologic investigations (SPECT/CT and/or MRI) and follow up at least one year.

SPETCT/CT scanning

All examinations were carried out using a SPECT/CT scanner (Philips, Netherlands,16-slice diagnostic CT). The whole-body scan was performed 3 h after intravenous injection of 15 ~ 25 mCi 99mTc-MDP. The images were immediately reviewed by a nuclear medicine radiologist after image acquisition. If areas of abnormal radiotracer uptake were detected, the patient then proceeded directly for SPECT/CT for anatomic location and attenuation correction of the areas. The acquisition parameters for CT were as following: 140KeV, window width 15%, pitch 1.25, and slice thickness 5.0 mm. Directly after CT imaging, the SPECT acquisition protocol was started. The SPECT/CT imaging was integrated and analyzed by using Philips Jet Steam Workspace integrated program. The coronal, sagittal and transverse plane of SPECT, CT and SPECT/CT was evaluated, respectively.

Imaging analysis

The WBS and SPECT/CT images were independently interpreted by two experienced nuclear medicine physician together with a diagnostic radiologist. In cases of discrepancy, consensus was obtained by a joint reading. It was considered high metabolism if the lesion showing uptake of 99mTc-MDP higher than that of sternum on WBS images, equal to that of sternum was considered moderate metabolism, and lower than that of sternum was considered low metabolism. The following radiologic features were evaluated on CT images: ground-glass opacity (GGO), expansion, lytic lesions, sclerosis, and cortical disruption (presence or absence).

Statistical analysis

Categorical data are expressed as numbers and frequency (%). Continuous data are expressed as means and standard deviations. All the statistical tests were performed using SPSS Statistics 17.0 (SPSS Inc., Chicago, IL, USA) software.

Result

Patient population

A summary of clinical characteristics (including age, gender, known malignancy and diagnostic method), WBS and SPECT/CT findings (including location and CT features) of all 21 patients with FD were given in Table 1. Nineteen of 21 patients (90.5%) were asymptomatic and detected incidentally on WBS. The remaining 2 patients (9.5%) presented with aspecific symptoms: one (patient 5) with nasal obstruction, and another (patient 12) with dull pain in left tibia. Only one patient (patient 14) (4.8%) was polyostotic and other 20 patients (95.2%) were monostotic. Lesions were most frequently found in craniofacial region, accounting for 71.4% (15/21) of patients, five of the patients in the skull, three in the maxillary, three in the mandible, three in sphenoid, and one patient showed conjoint sphenoid and ethmoid involvement. The remaining 6 patients, one patient with polyostotic lesion involvement of rib and vertebra, other 5 patients with solitary lesion in rib (n = 3), ischium (n = 1), and long bone (n = 1).
Table 1
Clinical data and SPECT/CT findings of FD in 21 patients with known cancer
Pat. No.
Localization
Known cancer
Diagnostic Method
GGO
Expansion
Lytic
Sclerosis
Cortical Disruption
1
Mandible
Lung cancer
Biopsy
+
+
2
Sphenoid
Gastric lymphoma
radiologic follow-up
+
+
3
Maxillary
Lung cancer
Biopsy
+
+
+
4
Sphenoid
HCC
radiologic follow-up
+
+
+
5
conjoint sphenoid and ethmoid
HCC
Biopsy
+
+
+
6
L. Rib
NPC
Biopsy
+
+
+
7
L. Frontal bone
Lung cancer
Biopsy
+
+
+
8
R. Parietal bone
ESCC
Biopsy
+
+
+
9
R. Frontal bone
LSCC
Biopsy
+
+
+
10
R. Ischium
Breast cancer
Biopsy
+
11
R. Occipital bone
NPC
Biopsy
+
+
12
L. Tibia
NPC
Biopsy
+
+
13
Maxillary
ESCC
radiologic follow-up
+
+
+
14
Rib, vertebra
HCC
radiologic follow-up
+
+
+
15
R. Frontal bone
ESCC
Biopsy
+
+
+
16
R. Rib
NPC
radiologic follow-up
+
+
+
17
Maxillary
Lung cancer
Biopsy
+
+
+
+
18
Maxillary
NPC
radiologic follow-up
+
+
19
Mandible
Cervical cancer
radiologic follow-up
+
+
20
Sphenoid
LSCC
radiologic follow-up
+
+
+
+
21
R. Rib
ESCC
Biopsy
+
+
+
+
Pat. No patient number, R right, L left, HCC hepatocellular carcinoma, NPC nasopharyngeal carcinoma, ESCC esophageal squamous carcinoma, LSCC laryngeal squamous carcinoma, GGO ground-glass opacity, + positive, negative.

WBS and SPECT/CT findings

Summary SPECT/CT features of 21 patients with FD were shown in Table 2. On WBS, all the lesions showed increased uptake of 99mTc-MDP. Among which, there were 18 of the 21 (85.7%) cases showed moderate and high metabolism (compared to sternum). Both GGO and Expansion were noted in vast majority of patients. GGO was present in 90.5% of patients (19/21, Figs. 1, 2, 3 and 4). Expansion was present in 85.7% of patients (18/21, Figs. 1, 2, 4). Lytic lesions were present in 13 patients (13/21, 61.9%, Fig. 4) with FD. Sclerosis was noted in only 8 patients (38.1%, Figs. 2, 3) with FD. Cortical disruption was not seen in any patients.
Table 2
Summary SPECT/CT features of 21 patients with FD
SPECT/CT findings
No. Patients(n)
Percentage (%)
Moderate and high metabolism
18
85.7%
GGO
19
90.5%
Expansion
18
85.7%
Lytic
13
61.9%
Sclerosis
8
38.1%
Cortical disruption
0
0
GGO ground-glass opacity

Discussion

WBS using 99mTc-MDP is one of the most frequently performed radionuclide procedures. Its excellent sensitivity makes it useful in screening for generalized bone abnormalities, but with lower specificity due to trauma, inflammation, and other malignant or benign bone diseases [68]. In some previous case reports, it has been recognized as being metabolically active on WBS [35]. However, the diagnosis of FD could not always be established only by WBS, which often needs to combine with an anatomical imaging (such as X-ray, CT, or MRI). Hybrid SPECT/spiral CT offers the opportunity to obtain diagnostic-quality CT and SPECT images, which provides a clear view of the anatomic sites of the lesions showed elevated 99mTc-MDP uptake [9, 10].
Of the cases examined in present study, all the patients showed increased uptake of 99mTc-MDP on WBS. Eighteen of the 21 (85.7%) cases showed moderate and high metabolism. The mechanism of different degree of 99mTc-MDP metabolism of FD is unclear. One reason can be accounted for that. As we known, FD is a developmental failure in the remodeling of primitive bone to mature lamellar bone. Fibroblasts are the predominant proliferating cells in FD lesions, and the different degree of 99mTc-MDP metabolism among FD may be due to the difference in the amount of proliferating fibroblasts or their metabolic turnover [11].Tracers uptake of FD have also been found in PET/CT, including radionuclide of 68Ga, 18F–fluorodeoxyglucose and 11C–choline [1214].
On SPECT/CT imaging, GGO and expansion were the most common findings, noted in 90.5% and 85.7% of the cases. Lytic lesions were present in 61.9% of the cases, and sclerosis was present in 38.1% of the cases. Cortical disruption was not seen in any patients. Some previous studies have reported that the typical CT features of FD are ground-glass opacity (GGO) and expansion of the bone, due to the simultaneous presence of bone trabeculae and fibrous tissue [1517]. Given these result, GGO and expansion appear to be reliable CT feature for diagnosis of fibro-osseous lesions. The differential diagnosis should include the other fibro-osseous diseases (ossifying fibroma and osseous dysplasia) and Paget disease [18].
The management of FD is not surgical unless it causes progressive deformity, cranial nerve compromise, pain, or malignant transformation. A malignant transformation of FD is rare, which occurs less than 1% of cases [19, 20]. In present study, the clinicians performed biopsy or surgery for 13 of the patients. All pathological results were reported as fibrous dysplasia, and no malignancy changes were detected. Some previous studies have reported that a history of radiotherapy may result in malignant transformation of FD [21]. Long-term medical imaging monitoring of FD is essential, especially in patient with a history of radiotherapy.

Conclusions

In conclusion, FD has certain characteristic appearance on SPECT/CT. It should be enrolled in the differential diagnoses when lesions show elevated 99mTc-MDP uptake on WBS image. On SPECT/CT image, the CT features of GGO and expansion in the areas of abnormal radiotracer uptake are helpful for the diagnosis of FD.

Acknowledgements

The authors thank Dr.Xi Zhong for his help of SPECT/CT images interpretation.

Funding

This work was supported by the Youth Foundation of Guangzhou Medical University (No.2016A24).

Availability of data and materials

The dataset supporting the conclusions of this article is included within the article.
Data and materials during the current study are available from the corresponding author on reasonable request.
Current study was approved by the Institutional Ethics Committee of the Affiliated Cancer Hospital&Institute of Guangzhou Medical University(No. 2017003) and need for signed informed consent was waived.
Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Benhamou J, Gensburger D, Messiaen C, Chapurlat R. Prognostic factors from an epidemiologic evaluation of fibrous dysplasia of bone in a modern cohort: the FRANCEDYS study. J Bone Miner Res. 2016;31(12):2167–72.CrossRefPubMed Benhamou J, Gensburger D, Messiaen C, Chapurlat R. Prognostic factors from an epidemiologic evaluation of fibrous dysplasia of bone in a modern cohort: the FRANCEDYS study. J Bone Miner Res. 2016;31(12):2167–72.CrossRefPubMed
2.
Zurück zum Zitat DiCaprio MR, Enneking WF. Fibrous dysplasia. Pathophysiology, evaluation, and treatment. J Bone Joint Surg Am. 2005;87(8):1848–64.PubMed DiCaprio MR, Enneking WF. Fibrous dysplasia. Pathophysiology, evaluation, and treatment. J Bone Joint Surg Am. 2005;87(8):1848–64.PubMed
3.
Zurück zum Zitat Nakahara T, Fujii H, Hashimoto J, Kubo A. Use of bone SPECT in the evaluation of fibrous dysplasia of the skull. Clin Nucl Med. 2004;29(9):554–9.CrossRefPubMed Nakahara T, Fujii H, Hashimoto J, Kubo A. Use of bone SPECT in the evaluation of fibrous dysplasia of the skull. Clin Nucl Med. 2004;29(9):554–9.CrossRefPubMed
4.
Zurück zum Zitat Rambalde E, Parra A, Santapau A, Tardin L, Freile E, Banzo J. SPECT/CT with (9)(9)mTc-MDP in a patient with monostotic fibrous dysplasia of the rib. Rev Esp Med Nucl Imagen Mol. 2013;32(2):126–7.PubMed Rambalde E, Parra A, Santapau A, Tardin L, Freile E, Banzo J. SPECT/CT with (9)(9)mTc-MDP in a patient with monostotic fibrous dysplasia of the rib. Rev Esp Med Nucl Imagen Mol. 2013;32(2):126–7.PubMed
5.
Zurück zum Zitat Tuncel M, Kiratli PO, Gedikoglu G. SPECT-CT imaging of poliostotic fibrous dysplasia. Rev Esp Med Nucl Imagen Mol. 2012;31(1):47–8.PubMed Tuncel M, Kiratli PO, Gedikoglu G. SPECT-CT imaging of poliostotic fibrous dysplasia. Rev Esp Med Nucl Imagen Mol. 2012;31(1):47–8.PubMed
6.
Zurück zum Zitat Gnanasegaran G, Ballinger JR. Molecular imaging agents for SPECT (and SPECT/CT). Eur J Nucl Med Mol Imaging. 2014;41(Suppl 1):S26–35.CrossRefPubMed Gnanasegaran G, Ballinger JR. Molecular imaging agents for SPECT (and SPECT/CT). Eur J Nucl Med Mol Imaging. 2014;41(Suppl 1):S26–35.CrossRefPubMed
7.
Zurück zum Zitat Huellner MW, Strobel K. Clinical applications of SPECT/CT in imaging the extremities. Eur J Nucl Med Mol Imaging. 2014;41(Suppl 1):S50–8.CrossRefPubMed Huellner MW, Strobel K. Clinical applications of SPECT/CT in imaging the extremities. Eur J Nucl Med Mol Imaging. 2014;41(Suppl 1):S50–8.CrossRefPubMed
8.
Zurück zum Zitat Helyar V, Mohan HK, Barwick T, Livieratos L, Gnanasegaran G, Clarke SE, Fogelman I. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging. 2010;37(4):706–13.CrossRefPubMed Helyar V, Mohan HK, Barwick T, Livieratos L, Gnanasegaran G, Clarke SE, Fogelman I. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging. 2010;37(4):706–13.CrossRefPubMed
9.
Zurück zum Zitat Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, Turler A, Vorreuther R, Gohring U, Schild HH, Gerhardt T, et al. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging. 2014;41(1):59–67.CrossRefPubMed Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, Turler A, Vorreuther R, Gohring U, Schild HH, Gerhardt T, et al. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging. 2014;41(1):59–67.CrossRefPubMed
10.
Zurück zum Zitat Abikhzer G, Srour S, Keidar Z, Bar-Shalom R, Kagna O, Israel O, Militianu D. Added value of SPECT/CT in the evaluation of benign bone diseases of the Appendicular skeleton. Clin Nucl Med. 2016;41(4):e195–9.CrossRefPubMed Abikhzer G, Srour S, Keidar Z, Bar-Shalom R, Kagna O, Israel O, Militianu D. Added value of SPECT/CT in the evaluation of benign bone diseases of the Appendicular skeleton. Clin Nucl Med. 2016;41(4):e195–9.CrossRefPubMed
11.
Zurück zum Zitat Zhao Z, Li L, Li FL. Radiography, bone scintigraphy, SPECT/CT and MRI of fibrous dysplasia of the third lumbar vertebra. Clin Nucl Med. 2009;34(12):898–901.CrossRefPubMed Zhao Z, Li L, Li FL. Radiography, bone scintigraphy, SPECT/CT and MRI of fibrous dysplasia of the third lumbar vertebra. Clin Nucl Med. 2009;34(12):898–901.CrossRefPubMed
12.
Zurück zum Zitat Papadakis GZ, Millo C, Sadowski SM, Karantanas AH, Bagci U, Patronas NJ. Fibrous dysplasia mimicking malignancy on 68Ga-DOTATATE PET/CT. Clin Nucl Med. 2017;42(3):209–10.PubMed Papadakis GZ, Millo C, Sadowski SM, Karantanas AH, Bagci U, Patronas NJ. Fibrous dysplasia mimicking malignancy on 68Ga-DOTATATE PET/CT. Clin Nucl Med. 2017;42(3):209–10.PubMed
13.
Zurück zum Zitat Gu CN, Hunt CH, Lehman VT, Johnson GB, Diehn FE, Schwartz KM, Eckel LJ. Benign fibrous dysplasia on [(11)C]choline PET: a potential mimicker of disease in patients with biochemical recurrence of prostate cancer. Ann Nucl Med. 2012;26(7):599–602.CrossRefPubMed Gu CN, Hunt CH, Lehman VT, Johnson GB, Diehn FE, Schwartz KM, Eckel LJ. Benign fibrous dysplasia on [(11)C]choline PET: a potential mimicker of disease in patients with biochemical recurrence of prostate cancer. Ann Nucl Med. 2012;26(7):599–602.CrossRefPubMed
14.
Zurück zum Zitat Strobel K, Bode B, Lardinois D, Exner U. PET-positive fibrous dysplasia--a potentially misleading incidental finding in a patient with intimal sarcoma of the pulmonary artery. Skelet Radiol. 2007;36(Suppl 1):S24–8.CrossRef Strobel K, Bode B, Lardinois D, Exner U. PET-positive fibrous dysplasia--a potentially misleading incidental finding in a patient with intimal sarcoma of the pulmonary artery. Skelet Radiol. 2007;36(Suppl 1):S24–8.CrossRef
15.
Zurück zum Zitat Sirvanci M, Karaman K, Onat L, Duran C, Ulusoy OL. Monostotic fibrous dysplasia of the clivus: MRI and CT findings. Neuroradiology. 2002;44(10):847–50.CrossRefPubMed Sirvanci M, Karaman K, Onat L, Duran C, Ulusoy OL. Monostotic fibrous dysplasia of the clivus: MRI and CT findings. Neuroradiology. 2002;44(10):847–50.CrossRefPubMed
16.
Zurück zum Zitat Unal Erzurumlu Z, Celenk P, Bulut E, Baris YS. CT imaging of craniofacial fibrous dysplasia. Case Rep Dent. 2015;2015:134123.PubMedPubMedCentral Unal Erzurumlu Z, Celenk P, Bulut E, Baris YS. CT imaging of craniofacial fibrous dysplasia. Case Rep Dent. 2015;2015:134123.PubMedPubMedCentral
17.
18.
Zurück zum Zitat Fusconi M, Conte M, Pagliarella M, De Vincentiis C, De Virgilio A, Benincasa AT, Alessi S, Gallo A. Fibrous dysplasia of the maxilla: diagnostic reliability of the study image. Literature review. J Neurol Surg B Skull Base. 2013;74(6):364–8.CrossRefPubMedPubMedCentral Fusconi M, Conte M, Pagliarella M, De Vincentiis C, De Virgilio A, Benincasa AT, Alessi S, Gallo A. Fibrous dysplasia of the maxilla: diagnostic reliability of the study image. Literature review. J Neurol Surg B Skull Base. 2013;74(6):364–8.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Qu N, Yao W, Cui X, Zhang H. Malignant transformation in monostotic fibrous dysplasia: clinical features, imaging features, outcomes in 10 patients, and review. Medicine (Baltimore). 2015;94(3):e369.CrossRef Qu N, Yao W, Cui X, Zhang H. Malignant transformation in monostotic fibrous dysplasia: clinical features, imaging features, outcomes in 10 patients, and review. Medicine (Baltimore). 2015;94(3):e369.CrossRef
20.
Zurück zum Zitat Mardekian SK, Tuluc M. Malignant sarcomatous transformation of fibrous dysplasia. Head Neck Pathol. 2015;9(1):100–3.CrossRefPubMed Mardekian SK, Tuluc M. Malignant sarcomatous transformation of fibrous dysplasia. Head Neck Pathol. 2015;9(1):100–3.CrossRefPubMed
21.
Zurück zum Zitat Mock D, Rosen IB. Osteosarcoma in irradiated fibrous dysplasia. J Oral Pathol. 1986;15(1):1–4.CrossRefPubMed Mock D, Rosen IB. Osteosarcoma in irradiated fibrous dysplasia. J Oral Pathol. 1986;15(1):1–4.CrossRefPubMed
Metadaten
Titel
The value of 99mTc-methylene diphosphonate single photon emission computed tomography/computed tomography in diagnosis of fibrous dysplasia
verfasst von
Linqi Zhang
Qiao He
Wei Li
Rusen Zhang
Publikationsdatum
01.12.2017
Verlag
BioMed Central
Erschienen in
BMC Medical Imaging / Ausgabe 1/2017
Elektronische ISSN: 1471-2342
DOI
https://doi.org/10.1186/s12880-017-0218-4

Weitere Artikel der Ausgabe 1/2017

BMC Medical Imaging 1/2017 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.